

# Karen Kelly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3465947/publications.pdf>

Version: 2024-02-01

154  
papers

12,601  
citations

36203

51  
h-index

24915

109  
g-index

157  
all docs

157  
docs citations

157  
times ranked

13468  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Nonâ€“Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2003, 290, 2149.	3.8	2,360
2	Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Nonâ€“Small-Cell Lung Cancer: A Southwest Oncology Group Trial. Journal of Clinical Oncology, 2001, 19, 3210-3218.	0.8	1,072
3	Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Nonâ€“Small-Cell Lung Cancer: SWOC S0023. Journal of Clinical Oncology, 2008, 26, 2450-2456.	0.8	555
4	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nature Medicine, 2019, 25, 141-151.	15.2	539
5	Avelumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, in Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. Journal of Clinical Oncology, 2017, 35, 2117-2124.	0.8	538
6	Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-III A Nonâ€“Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2015, 33, 4007-4014.	0.8	392
7	Twenty years postâ€“NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual. Cancer, 2014, 120, 1091-1096.	2.0	323
8	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. JAMA Oncology, 2019, 5, 393.	3.4	303
9	Increased <i>EGFR</i> Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Nonâ€“Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. Journal of Clinical Oncology, 2008, 26, 3351-3357.	0.8	278
10	Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 803-811.	5.1	261
11	HER1/EGFR Inhibitorâ€“Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. Oncologist, 2005, 10, 345-356.	1.9	257
12	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 599-610.	5.1	257
13	Treatment of Advanced Nonâ€“Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel. Journal of Clinical Oncology, 2005, 23, 3125-3137.	0.8	185
14	Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8786-8793.	0.8	184
15	Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology, 2005, 23, 3752-3759.	0.8	176
16	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963.	0.5	173
17	Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Nonâ€“Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. Journal of Clinical Oncology, 2008, 26, 463-467.	0.8	172
18	Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer, 2008, 61, 82-90.	0.9	163

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5025-5033.	0.8	154
20	Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1441-1464.	2.3	146
21	Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4405-4411.	0.8	139
22	Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5533-5533.	0.8	117
23	Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 3567-3572.	0.8	110
24	Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers. <i>Cancer Prevention Research</i> , 2011, 4, 793-802.	0.7	104
25	A prognostic model for advanced stage nonsmall cell lung cancer. <i>Cancer</i> , 2006, 107, 781-792.	2.0	99
26	50 Years of Progress in the Systemic Therapy of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 177-189.	1.8	92
27	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3298-3306.	0.8	88
28	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	0.8	84
29	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018, 124, 2010-2017.	2.0	81
30	Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications. <i>Clinical Lung Cancer</i> , 2014, 15, 1-6.	1.1	79
31	Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma. <i>Cancer Prevention Research</i> , 2015, 8, 410-418.	0.7	79
32	Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?. <i>Lung Cancer</i> , 1998, 20, 85-91.	0.9	77
33	Long-Term Survival with Concurrent Chemoradiation Therapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small-Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S9504). <i>Clinical Lung Cancer</i> , 2006, 8, 116-121.	1.1	77
34	Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2480-2486.	3.2	70
35	New Chemotherapy Agents for Small Cell Lung Cancer. <i>Chest</i> , 2000, 117, 156S-162S.	0.4	69
36	Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2463-2470.	0.8	69

#	ARTICLE	IF	CITATIONS
37	Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis. <i>Lung Cancer</i> , 2014, 85, 264-269.	0.9	68
38	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , 2017, 35, 2885-2892.	0.8	68
39	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlo	5.1	68
40	Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study S0342. <i>Journal of Clinical Oncology</i> , 2010, 28, 4747-4754.	0.8	66
41	Biological Markers for Non-Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3652-3656.	3.2	62
42	Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1685-1693.	0.5	62
43	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 101-114.	5.1	62
44	SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1847-1852.	0.5	62
45	<i>N</i> -Glycan Profiling of Dried Blood Spots. <i>Analytical Chemistry</i> , 2012, 84, 396-402.	3.2	60
46	Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. <i>Clinical Cancer Research</i> , 2015, 21, 4321-4326.	3.2	59
47	Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue. <i>Journal of Proteome Research</i> , 2015, 14, 4538-4549.	1.8	59
48	Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1716-1723.	1.1	58
49	The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1636-1645.	0.5	58
50	SWOG S1400C (NCT02154490) A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1853-1859.	0.5	58
51	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1368.	3.4	57
52	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1259-1270.	0.4	54
53	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1839-1846.	0.5	53
54	Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 87-94.	0.8	51

#	ARTICLE	IF	CITATIONS
55	Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG) Tj ETQq1 1 0.784314 rgBT / Ov	3.2	49
56	Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5439-5446.	3.2	49
57	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1075114.	2.1	47
58	Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509. <i>Journal of Thoracic Oncology</i> , 2011, 6, 115-120.	0.5	43
59	Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 437-445.	0.5	43
60	A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. <i>Clinical Lung Cancer</i> , 2015, 16, 340-347.	1.1	42
61	Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. <i>Cancer Biomarkers</i> , 2016, 16, 609-617.	0.8	42
62	A Phase II Study of Telisotuzumab Vedotin in Patients With MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , 2021, 22, 170-177.	1.1	41
63	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 556-566.	0.5	40
64	Current Treatment Paradigms for Locally Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S77-S85.	0.5	36
65	Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). <i>Journal of Clinical Oncology</i> , 2019, 37, 2537-2547.	0.8	36
66	Biological Agents in Non-small Cell Lung Cancer: A Review of Recent Advances and Clinical Results with a Focus on Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor. <i>Journal of Thoracic Oncology</i> , 2008, 3, 664-673.	0.5	35
67	Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 4953-4958.	1.9	35
68	Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 281-285.	1.1	35
69	Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). <i>Journal of the National Cancer Institute</i> , 2018, 110, 734-742.	3.0	32
70	ACCO: ASCO Core Curriculum Outline. <i>Journal of Clinical Oncology</i> , 2005, 23, 2049-2077.	0.8	31
71	The inherited nature of lung cancer: a pilot study. <i>Lung Cancer</i> , 2000, 30, 135-144.	0.9	30
72	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5781-5792.	3.2	30

#	ARTICLE	IF	CITATIONS
73	Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. <i>Lung Cancer</i> , 2017, 112, 165-168.	0.9	29
74	Detection of K-ras Oncogene Mutations by Polymerase Chain Reaction-Based Ligase Chain Reaction. <i>Analytical Biochemistry</i> , 1996, 239, 153-159.	1.1	28
75	A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without $\hat{\pm}$ Tocopherol or Observation in Subjects at High Risk for Lung Cancer. <i>Cancer Prevention Research</i> , 2009, 2, 440-449.	0.7	28
76	Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. <i>Seminars in Oncology</i> , 2004, 31, 3-7.	0.8	26
77	A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S120-S127.	0.4	26
78	Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Inpatient Tumor Heterogeneity. <i>Clinical Lung Cancer</i> , 2012, 13, 321-325.	1.1	26
79	Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices. <i>Briefings in Bioinformatics</i> , 2016, 18, bbw010.	3.2	26
80	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). , 2021, 9, e002973.		26
81	Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non- Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1041-1048.	0.5	25
82	Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials. <i>Journal of Thoracic Oncology</i> , 2015, 10, 110-115.	0.5	25
83	Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1299-1308.	0.5	24
84	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. , 2021, 9, e002015.		23
85	A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 7229-7237.	3.2	22
86	Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non- Small-Cell Lung Cancer: SWOG S0536. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1519-1528.	0.5	22
87	Phase 1B Study of Mometinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non- Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. <i>Clinical Lung Cancer</i> , 2018, 19, e853-e859.	1.1	21
88	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. <i>Oncologist</i> , 2019, 24, 1270-1284.	1.9	21
89	Survival benefits associated with surgery for advanced non- small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1620-1628.	0.4	19
90	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non- Small Cell Lung Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2018, 24, 5543-5551.	3.2	18

#	ARTICLE	IF	CITATIONS
91	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). <i>Clinical Cancer Research</i> , 2022, 28, 3752-3760.	3.2	18
92	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1171-1182.	0.5	17
93	Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 372-377.	0.5	16
94	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
95	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. , 2020, 8, e001064.		16
96	Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 1, 177-190.	1.5	16
97	Efficacy and safety of gefitinib in chemo-naïve patients with advanced non-small cell lung cancer treated in an Expanded Access Program. <i>Lung Cancer</i> , 2006, 53, 331-337.	0.9	15
98	Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 4165-4172.	2.0	15
99	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 1-4.	1.1	14
100	A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1665-1672.	0.7	13
101	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 298-303.	0.5	13
102	Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: Assays for promotion factors in the bronchial lavage. <i>Journal of Cellular Biochemistry</i> , 1993, 53, 175-183.	1.2	12
103	A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 40, 559-567.	0.4	12
104	Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy. <i>Clinical Lung Cancer</i> , 2013, 14, 627-635.	1.1	12
105	A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 219.	1.3	12
106	The Role of Targeted Agents in Adjuvant Therapy for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5027s-5029s.	3.2	11
107	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021, 13, 727-734.	1.0	11
108	Single-Institution Experience with Pemetrexed and Bevacizumab as Salvage Therapy in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2007, 8, 335-338.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. <i>Clinical Lung Cancer</i> , 2016, 17, 113-118.e2.	1.1	10
110	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3055-3055.	0.8	10
111	EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. <i>Lancet Oncology</i> , The, 2007, 8, 559-560.	5.1	9
112	Treatment of Locally Advanced Nonâ€“Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 45-57.	0.9	9
113	Growth factors in lung cancer: Possible etiologic role and clinical target. <i>Medical and Pediatric Oncology</i> , 1991, 19, 449-458.	1.0	8
114	Peptide amidating activity in human bronchoalveolar lavage fluid. <i>Lung Cancer</i> , 1996, 14, 239-251.	0.9	8
115	Treatment of Thymoma: A Comparative Study Between Thailand and the United States and a Review of the Literature. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 236-246.	0.6	8
116	Novel approaches for the treatment of small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 499-518.	0.9	7
117	A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. <i>Investigational New Drugs</i> , 2006, 24, 213-221.	1.2	7
118	Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Nonâ€“Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, 84-92.	1.1	7
119	Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 335-341.	1.1	7
120	SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7018-7018.	0.8	7
121	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100262.	0.6	7
122	Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 301.	1.3	6
123	Clinical prognostic model for older patients with advanced non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 555-559.	0.5	6
124	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	3.2	6
125	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.	1.1	6
126	The benefits of achieving stable disease in advanced lung cancer. <i>Oncology</i> , 2003, 17, 957-63; discussion 963, 968-70.	0.4	6



#	ARTICLE	IF	CITATIONS
127	Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2007, 2, 933-938.	0.5	5
128	A phase I trial of topotecan plus tivatinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 723-732.	1.1	5
129	Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e15-e20.	1.1	5
130	Guidelines for the Evaluation of Pulmonary Nodules Detected Incidentally or by Screening: A Survey of Radiologist Awareness, Agreement, and Adherence From the Watch the Spot Trial. <i>Journal of the American College of Radiology</i> , 2021, 18, 545-553.	0.9	5
131	Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914. <i>Journal of Thoracic Oncology</i> , 2006, 1, 991-995.	0.5	5
132	EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. <i>Clinical Lung Cancer</i> , 2022, 23, 60-71.	1.1	5
133	Re: Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 1995, 87, 767-767.	3.0	4
134	Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718. <i>Journal of Thoracic Oncology</i> , 2007, 2, 440-444.	0.5	4
135	CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 225-231.	1.1	4
136	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , 2021, 17, e1821-e1829.	1.4	4
137	Infusion-related reactions with administration of avelumab: mild and manageable side effects. <i>Translational Cancer Research</i> , 2017, 6, S1296-S1298.	0.4	4
138	Treatment paradigms in advanced non-small-cell lung cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 629-39.	0.3	4
139	Therapeutic Strategies for Combined-Modality Therapy of Locally Advanced-Stage Non-small-Cell Lung Cancer: Rationale for Consolidation Docetaxel Therapy. <i>Clinical Lung Cancer</i> , 2005, 7, S93-S97.	1.1	3
140	The Ever-Increasing Number of Trial Eligibility Criteria: Time to Bend the Curve. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1459-1460.	0.5	3
141	Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens. <i>Bioinformatics</i> , 2017, 33, 17-25.	1.8	3
142	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-small-cell Lung Cancer With Different Prognostic Significance. <i>Clinical Lung Cancer</i> , 2018, 19, 531-543.	1.1	3
143	Current role of irinotecan in the treatment of non-small-cell lung cancer. <i>Oncology</i> , 2002, 16, 1153-62, 1165; discussion 1165-6 passim.	0.4	3
144	Antigens in lung cancer: clinical radio-immunolocalization in lung cancer. <i>Lung Cancer</i> , 1993, 9, 171-177.	0.9	2

#	ARTICLE	IF	CITATIONS
145	Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914. <i>Journal of Thoracic Oncology</i> , 2006, 1, 991-995.	0.5	1
146	Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3057-3057.	0.8	1
147	Long-term avelumab in advanced non-small-cell lung cancer: summaries and <i>post hoc</i> analyses from JAVELIN Solid Tumor. <i>Future Oncology</i> , 2022, 18, 1333-1342.	1.1	1
148	Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium. <i>Journal of Thoracic Oncology</i> , 2009, 4, 930-935.	0.5	0
149	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 75-85.	1.5	0
150	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, 377-386.	1.1	0
151	Treatment of Extensive-Stage Small Cell Lung Cancer. , 2018, , 525-535.e5.		0
152	Response to H. Nabi et al.. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1424-1425.	3.0	0
153	IMpower 132: Loses Power at the Finish Line. <i>Journal of Thoracic Oncology</i> , 2021, 16, 512-514.	0.5	0
154	An elderly man with resectable lung cancer. <i>Oncology</i> , 2004, 18, 234-40.	0.4	0